A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer

被引：45

作者：

Wu, Xiujuan ^{[1
]}

Tang, Peng ^{[1
]}

Li, Shifei ^{[1
]}

Wang, Shushu ^{[1
]}

Liang, Yueyang ^{[1
]}

Zhong, Ling ^{[1
]}

Ren, Lin ^{[1
]}

Zhang, Ting ^{[1
]}

Zhang, Yi ^{[1
]}

机构：

[1] Third Mil Med Univ, Southwest Hosp, Breast Dis Ctr, Chongqing 400038, Peoples R China

来源：

NATURE COMMUNICATIONS | 2018年 / 9卷

关键词：

PATHOLOGICAL COMPLETE RESPONSE; ARTERIAL CHEMOEMBOLIZATION; ANTITUMOR-ACTIVITY; CHEMOTHERAPY; DOCETAXEL; CARBOPLATIN; EPIRUBICIN; PACLITAXEL; CISPLATIN; DOXORUBICIN;

D O I：

10.1038/s41467-018-03210-2

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Currently, one sixth of triple-negative breast cancer (TNBC) patients who receive docetaxel (T) and epirubicin (E) as neoadjuvant chemotherapy achieve a pathologic complete response (pCR). This study evaluates the impact of adding lobaplatin (L) to the TE regimen. Here, we show data from 125 patients (63 TE and 62 TEL patients). Four patients did not complete all the cycles. Two-sided P values show that the addition of L (38.7% vs. 12.7%, P = 0.001) significantly increases the rate of pCR in the breast and the axilla (TpCR) and the overall response rate (ORR; 93.5% vs. 73.0%, P = 0.003). The occurrence of grade 3-4 anemia and thrombocytopenia is higher in the TEL group (52.5% vs. 10.0% and 34.4% vs. 1.7% respectively). These results demonstrate that the addition of L to the TE regimen as neoadjuvant chemotherapy improves the TpCR and the ORR rates of TNBC but with increased side effects.

引用

页数：8

共 50 条

[1] A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer
Xiujuan Wu
Peng Tang
Shifei Li
Shushu Wang
Yueyang Liang
Ling Zhong
Lin Ren
Ting Zhang
Yi Zhang
Nature Communications, 9
[2] Lobaplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: a 5-year follow-up of a randomized, open-label, phase II trial
Yan, Wenting
Wu, Xiujuan
Wang, Shushu
He, Cheng
Zhong, Ling
Tang, Peng
Ren, Lin
Zhang, Ting
Qi, Xiaowei
Zhang, Yi
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
[3] A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer
Yan, Min
Yuan, Peng
Ouyang, Quchang
Cheng, Ying
Han, Guohui
Wang, Dewei
Ran, Li
Sun, Tao
Zhao, Da
Bai, Yuju
Yang, Shun'e
Wang, Xiaojia
Wu, Rong
Zeng, Xiaohua
Yao, Herui
Ji, Xuening
Jiang, Jun
Hu, Xiaohua
Lin, Haifeng
Zheng, Liping
Zhu, Zhitu
Ge, Wei
Yang, Junlan
Cui, Tongjian
Zhang, Xiaozhi
Lu, Fangyang
Li, Wenhui
Xu, Hongyan
Kang, Mafei
Gong, Ping
Zou, Liqun
Liu, Jiang
Zhang, Hongliang
Yu, Hao
Xu, Binghe
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
[4] A prospective, open-label, multicenter, phase IV clinical study on the safety and efficacy of lobaplatin in the treatment of metastatic breast cancer.
Xu, Binghe
Yan, Min
Ouyang, Quchang
Han, Guohui
Cheng, Ying
Wang, Dewei
Li, Ran
Zhao, Da
Sun, Tao
Bai, Yuju
Yu, Hao
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[5] Neoadjuvant chemoradiotherapy with ipilimumab and nivolumab in rectal cancer (CHINOREC): A prospective randomized, open-label, multicenter, phase II clinical trial.
Laengle, Johannes
Kuehrer, Irene
Kulu, Askin
Kabiljo, Julijan
Ammon, Daphni
Zirnbauer, Rebecca
Stift, Anton
Herbst, Friedrich
Dauser, Bernhard
Monschein, Matthias
Razek, Peter
Biebl, Matthias
Geinitz, Hans
Hulla, Wolfgang
Muellauer, Leonhard
Widder, Joachim
Bittermann, Clemens
Laengle, Friedrich
Schmid, Rainer
Bergmann, Michael M.
CHINOREC Study Grp
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 139 - 139
[6] NEOADJUVANT CHEMORADIOTHERAPY WITH SEQUENTIAL IPILIMUMAB AND NIVOLUMAB IN RECTAL CANCER (CHINOREC): A PROSPECTIVE RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II CLINICAL TRIAL
Laengle, J.
Kuehrer, I.
Pils, D.
Kabiljo, J.
Woeran, K.
Stift, J.
Herbst, F.
Dauser, B.
Monschein, M.
Razek, P.
Haegele, S.
Herac, M.
Hulla, W.
Bitterman, C.
Laengle, F.
Tamandl, D.
Widder, J.
Schmid, R.
Bergmann, M.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A51 - A51
[7] Efficacy of RestoreX after prostatectomy: open-label phase of a randomized controlled trial
Zganjar, Andrew
Toussi, Amir
Ziegelmann, Matthew
Frank, Igor
Boorjian, Stephen A. A.
Tollefson, Matthew
Kohler, Tobias
Trost, Landon
BJU INTERNATIONAL, 2023, 132 (02) : 217 - 226
[8] Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
Liu, Jieqiong
Liu, Qiang
Li, Ying
Li, Qian
Su, Fengxi
Yao, Herui
Su, Shicheng
Wang, Quanren
Jin, Liang
Wang, Ying
Lau, Wan Yee
Jiang, Zefei
Song, Erwei
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
[9] A Neoadjuvant, Randomized, Open-Label Phase II Trial of Afatinib Versus Trastuzumab Versus Lapatinib in Patients With Locally Advanced HER2-Positive Breast Cancer
Rimawi, Mothaffar F.
Aleixo, Sabina B.
Alarcon Rozas, Ashley
de Matos Neto, Joao Nunes
Caleffi, Maira
Figueira, Alicardo Cesar
Souza, Sulene Cunha
Reiriz, Andre B.
Gutierrez, Carolina
Arantes, Heloisa
Uttenreuther-Fischer, Martina M.
Solca, Flavio
Osborne, C. Kent
CLINICAL BREAST CANCER, 2015, 15 (02) : 101 - 109
[10] Neoadjuvant chemoradiotherapy with sequential ipilimumab and nivolumab in rectal cancer (CHINOREC): A prospective randomized, open-label, multicenter, phase II clinical trial.
Laengle, Johannes
Kuehrer, Irene
Pils, Dietmar
Kabiljo, Julijan
Stift, Judith
Herbst, Friedrich
Dauser, Bernhard
Monschein, Matthias
Razek, Peter
Haegele, Stefanie
Huller, Wolfgang
Fuegger, Reinhold
Geinitz, Hans
Petzer, Andreas L.
Bitterman, Clemens
Laengle, Friedrich
Tamandl, Dietmar
Widder, Joachim
Schmid, Rainer
Bergmann, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →